Jeffrey E Lancet (Jeffrey Lancet)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 20

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

American journal of hematology

Blood cancer journal

Cancer communications (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, David A Sallman, Justine Decroocq, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Chantal Himberlin, Pierre Peterlin, Sarah Bonnet, Onyee Chan, Jeffrey E Lancet, Rami Komrokji, François Vergez, Nicolas Chapuis, Tatiana Raskovalova, Adriana Plesa, Anne-Catherine Lhoumeau, Ariane Mineur, Marie Anne Hospital, Arnaud Pigneux, Norbert Vey, Christian Recher
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. American journal of hematology (2024)
Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, David A Sallman, Justine Decroocq, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Chantal Himberlin, Pierre Peterlin, Sarah Bonnet, Onyee Chan, Jeffrey E Lancet, Rami Komrokji, François Vergez, Nicolas Chapuis, Tatiana Raskovalova, Adriana Plesa, Anne-Catherine Lhoumeau, Ariane Mineur, Marie Anne Hospital, Arnaud Pigneux, Norbert Vey, Christian Recher
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. American journal of hematology (2024)
Parth C Patel, Somedeb Ball, Akriti Gupta Jain, Chen Wang, Mohammad O Hussaini, Luis E Aguirre, Onyee Chan, Seongseok Yun, Andrew T Kuykendall, Eric Padron, Kendra L Sweet, Jeffrey E Lancet, Rami S Komrokji, David A Sallman
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia. American journal of hematology (2023)
Qianxing Mo, Seongseok Yun, David A Sallman, Nicole D Vincelette, Guang Peng, Ling Zhang, Jeffrey E Lancet, Eric Padron
Integrative molecular subtypes of acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Qianxing Mo, Seongseok Yun, David A Sallman, Nicole D Vincelette, Guang Peng, Ling Zhang, Jeffrey E Lancet, Eric Padron
Integrative molecular subtypes of acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Anna Giuliano, Barbara Kuter, Shari Pilon-Thomas, Junmin Whiting, Qianxing Mo, Brett Leav, Bradley Sirak, Christopher Cubitt, Christopher W Dukes, Kimberly Isaacs-Soriano, Kayoko Kennedy, Somedeb Ball, Ning Dong, Akriti Jain, Patrick Hwu, Jeffrey E Lancet
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients. Cancer communications (London, England) (2023)
Luis E Aguirre, Najla Al Ali, David A Sallman, Somedeb Ball, Akriti G Jain, Onyee Chan, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, Rami S Komrokji
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia (2023)
Qianxing Mo, Seongseok Yun, David A Sallman, Nicole D Vincelette, Guang Peng, Ling Zhang, Jeffrey E Lancet, Eric Padron
Integrative molecular subtypes of acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Christopher T Letson, Maria E Balasis, Hannah Newman, Moritz Binder, Alexis Vedder, Fumi Kinose, Markus Ball, Traci Kruer, Ariel Quintana, Terra L Lasho, Christy M Finke, Luciana L Almada, Jennifer Margaret Grants, Guolin Zhang, Martin E Fernandez-Zapico, Alexandre Gaspar-Maia, Jeffrey E Lancet, Rami S Komrokji, Eric B Haura, David A Sallman, Gary W Reuther, Aly Karsan, Uwe Rix, Mirinal S Patnaik, Eric Padron
Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Qianxing Mo, Seongseok Yun, David A Sallman, Nicole D Vincelette, Guang Peng, Ling Zhang, Jeffrey E Lancet, Eric Padron
Integrative molecular subtypes of acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Rami S Komrokji, Avani M Singh, Najla Al Ali, Onyee Chan, Eric Padron, Kendra Sweet, Andrew Kuykendall, Jeffrey E Lancet, David A Sallman
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood cancer journal 12 (11) (2022)
Somedeb Ball, Akriti G Jain, Luis E Aguirre, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T Kuykendall, Kendra L Sweet, Jeffrey E Lancet, David M Swoboda, Eric Padron, Rami S Komrokji, David A Sallman
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better? American journal of hematology 97 (5) (2022)
David M Swoboda, Rashmi Kanagal-Shamana, Andrew M Brunner, Thomas Cluzeau, Onyee Chan, Najla Al Ali, Guillermo Montalban-Bravo, Quinto J Gesiotto, Alexander Gavralidis, Anthony M Hunter, Jung-Hoon Lee, Andrew T Kuykendall, Chetasi Talati, Kendra L Sweet, Jeffrey E Lancet, Eric Padron, Mohammad Hussaini, Jinming Song, Guillermo Garcia Manero, Rami S Komrokji, David A Sallman
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia 36 (4) (2022)
David M Swoboda, Najla Al Ali, Onyee Chan, Eric Padron, Andrew T Kuykendall, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra Sweet, Jeffrey E Lancet, David A Sallman, Rami S Komrokji
PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia 35 (1) (2020)
Rami S Komrokji, Najla Al Ali, David Sallman, Eric Padron, Jeffrey E Lancet, Lubomir Sokol, Christa Varnadoe, P K Burnette, Alan List
Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia 34 (11) (2020)
Seongseok Yun, Susan M Geyer, Rami S Komrokji, Najla H Al Ali, Jinming Song, Mohammad Hussaini, Kendra L Sweet, Jeffrey E Lancet, Alan F List, Eric Padron, David A Sallman
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia 35 (4) (2020)
Andrew T Kuykendall, Chetasi Talati, Eric Padron, Kendra L Sweet, Jeffrey E Lancet, Alan F List, David A Sallman, Rami S Komrokji
Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. American journal of hematology 94 (12) (2019)
Andrew T Kuykendall, Chetasi Talati, Eric Padron, Kendra L Sweet, David Sallman, Alan F List, Jeffrey E Lancet, Rami S Komrokji
Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. American journal of hematology 94 (1) (2018)
Patrick T Griffin, Rami S Komrokji, Kendra Sweet, Najla H Al Ali, Eric Padron, Timothy E Kubal, Alan F List, Jeffrey E Lancet
Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. American journal of hematology 92 (3) (2017)
Roland Bruno Walter, Laura C Michaelis, Megan Othus, Geoffrey L Uy, Jerald P Radich, Richard F Little, Sandi Hita, Lalit Saini, James M Foran, Aaron T Gerds, Heidi D Klepin, Annette E Hay, Sarit Assouline, Jeffrey E Lancet, Stephen Couban, Mark R Litzow, Richard M Stone, Harry P Erba
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. American journal of hematology 93 (2) (2017)